IDEAYA Biosciences Inc
IDYA32.170USD
+0.400+1.26%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
2.82BValor de mercado
PerdaP/L TTM
Mais detalhes de IDEAYA Biosciences Inc Empresa
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Informações de IDEAYA Biosciences Inc
Código da empresaIDYA
Nome da EmpresaIDEAYA Biosciences Inc
Data de listagemMay 23, 2019
CEOHata (Yujiro S)
Número de funcionários131
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 23
Endereço7000 Shoreline Ct, Suite 350
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone16504436209
Sitehttps://www.ideayabio.com/
Código da empresaIDYA
Data de listagemMay 23, 2019
CEOHata (Yujiro S)
Executivos da empresa IDEAYA Biosciences Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
Por EmpresaUSD
Nome
Receita
Proporção
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
United States
7.00M
100.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Distribuição de ações
Atualizado em: sáb, 7 de fev
Atualizado em: sáb, 7 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
15.00%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.33%
BlackRock Institutional Trust Company, N.A.
7.23%
The Vanguard Group, Inc.
5.70%
Outro
57.27%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
15.00%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.33%
BlackRock Institutional Trust Company, N.A.
7.23%
The Vanguard Group, Inc.
5.70%
Outro
57.27%
Tipos de investidores
Investidores
Proporção
Investment Advisor
49.41%
Investment Advisor/Hedge Fund
32.26%
Hedge Fund
19.91%
Research Firm
3.93%
Venture Capital
3.62%
Pension Fund
0.95%
Individual Investor
0.91%
Bank and Trust
0.45%
Insurance Company
0.07%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
489
96.76M
110.37%
-16.87M
2025Q3
460
105.73M
120.62%
-11.57M
2025Q2
449
101.70M
116.06%
-6.32M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
13.15M
15%
+9.25K
+0.07%
Sep 30, 2025
Capital Research Global Investors
6.55M
7.47%
--
--
Sep 30, 2025
Janus Henderson Investors
6.43M
7.33%
+222.10K
+3.58%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.34M
7.23%
-336.88K
-5.05%
Sep 30, 2025
The Vanguard Group, Inc.
4.90M
5.59%
-19.74K
-0.40%
Sep 30, 2025
Federated Hermes Global Investment Management Corp.
4.63M
5.28%
-1.42K
-0.03%
Sep 30, 2025
Point72 Asset Management, L.P.
3.82M
4.35%
-1.21M
-24.12%
Sep 30, 2025
Baker Bros. Advisors LP
3.28M
3.74%
+1.16M
+54.59%
Sep 30, 2025
State Street Investment Management (US)
3.24M
3.7%
-144.86K
-4.28%
Sep 30, 2025
Adage Capital Management, L.P.
2.90M
3.31%
+1.66M
+134.24%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Tema Oncology ETF
3.49%
ALPS Medical Breakthroughs ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
0.83%
State Street SPDR S&P Biotech ETF
0.72%
First Trust Innovation Leaders ETF
0.7%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
ProShares Ultra Nasdaq Biotechnology
0.38%
Avantis US Small Cap Equity ETF
0.29%
Invesco Nasdaq Biotechnology ETF
0.27%
Ver Mais
Tema Oncology ETF
Proporção3.49%
ALPS Medical Breakthroughs ETF
Proporção1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção0.83%
State Street SPDR S&P Biotech ETF
Proporção0.72%
First Trust Innovation Leaders ETF
Proporção0.7%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.45%
ProShares Ultra Nasdaq Biotechnology
Proporção0.38%
Avantis US Small Cap Equity ETF
Proporção0.29%
Invesco Nasdaq Biotechnology ETF
Proporção0.27%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
